<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04640610</url>
  </required_header>
  <id_info>
    <org_study_id>APHP201032</org_study_id>
    <nct_id>NCT04640610</nct_id>
  </id_info>
  <brief_title>Angiotensin-converting Enzyme 2 (ACE2) Expression in Tonsils and Adenoids</brief_title>
  <acronym>ACE2-AVG</acronym>
  <official_title>Study of the Expression of Angiotensin-converting Enzyme 2 (ACE2), a Cell Membrane Receptor for SARS-CoV-2 and the TMPRSS2 Serine Protease in Tonsils and Adenoids of Children and Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the research is to study the expression of the ACE 2 receptor and the&#xD;
      TMPRSS2 serine protease in the tonsils and adenoids of children and adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The entry point for SARS-CoV-2 into the body is the nasal and pharyngeal mucosa.&#xD;
      Angiotensin-converting enzyme 2 (ACE 2) was quickly identified as the functional receptor for&#xD;
      SARS-CoV-2. Furthermore, the TMPRSS2 serine protease is required for the anchoring of the S&#xD;
      protein in cell lines. In addition, the most commonly used screening test is a test for viral&#xD;
      RNA by RT-PCR on a nasopharyngeal sample because the viral load is high.&#xD;
&#xD;
      The tonsils and adenoids could be a target organ of the virus. In order to study this&#xD;
      hypothesis, the expression of ACE 2 and the serine protease TMPRSS2 will be sought in these&#xD;
      tissues.&#xD;
&#xD;
      In addition, children, generally at high risk of severe viral respiratory infections (RSV,&#xD;
      influenza), have milder symptoms than older patients with SARS-CoV-2 infection. The reason&#xD;
      for this difference remains elusive. But one of the hypotheses formulated is that the level&#xD;
      of expression of ACE 2 and / or TMPRSS2 may differ between adults and children, the viral&#xD;
      load seeming to be correlated with the severity of the attack. In order to study this&#xD;
      hypothesis, we will therefore compare the level of expression of ACE 2 in the tonsil tissue&#xD;
      of children and adults.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Abandonment of the study project&#xD;
  </why_stopped>
  <start_date type="Actual">June 30, 2021</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Expression of ACE 2 receptor and TMPRSS2 serine protease</measure>
    <time_frame>9 months</time_frame>
    <description>Measurement of expression of ACE 2 receptor and TMPRSS2 serine protease in tonsils and adenoids labeled by immunofluorescence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Location of ACE 2 receptor and TMPRSS2 serine protease</measure>
    <time_frame>9 months</time_frame>
    <description>Location of ACE 2 receptor and TMPRSS2 serine protease in tonsils and adenoids labeled by immunofluorescence.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Adenoidectomy</condition>
  <condition>Tonsillectomy</condition>
  <arm_group>
    <arm_group_label>Adenoidectomy / tonsillectomy</arm_group_label>
    <description>Children and adults, without SARS-CoV-2 infection, in whom an adenoidectomy and/or tonsillectomy is performed for their care in the centers of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Storage of operating waste</intervention_name>
    <description>Storage of operating waste of adenoidectomy / tonsillectomy</description>
    <arm_group_label>Adenoidectomy / tonsillectomy</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tonsils and adenoids preserved by cryopreservation and fixed with formalin.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children and adults, without SARS-CoV-2 infection, in whom an adenoidectomy and/or&#xD;
        tonsillectomy is performed for their care in the centers of the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children and adults, without SARS-CoV-2 infection, in whom an adenoidectomy and/or&#xD;
             tonsillectomy is performed for their care in the hospitals of Assistance&#xD;
             Publique-Hôpitaux de Paris participating in the study.&#xD;
&#xD;
          -  Holders of parental authority of minor patients and adult patients not opposed to&#xD;
             participation in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - N/A&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Romain Luscan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre-Louis Tharaux, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institut National de la Santé Et de la Recherche Médicale, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Armand Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HEGP</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 19, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2020</study_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Angiotensin-converting enzyme 2 (ACE2)</keyword>
  <keyword>Transmembrane serine protease 2 (TMPRSS2)</keyword>
  <keyword>Tonsils</keyword>
  <keyword>Adenoids</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

